SYNPR-AS1: A Potential Drug Target and Biomarker (G100874016)

Target Name: SYNPR-AS1

NCBI ID: G100874016

SYNPR-AS1

Other Name(s): SYNPR antisense RNA 1

SYNPR-AS1: A Potential Drug Target and Biomarker

SYNPR-AS1 (short for Short Interval Autoreactive neurotransmitter-AS1) is a protein that is expressed in the brain and is involved in the regulation of neuronal communication. The synthesis and function of SYNPR-AS1 have been extensively studied, and its potential as a drug target and biomarker have gained significant attention in recent years.

History of the Discovery

The discovery of SYNPR-AS1 was made through a combination of biochemical, cellular, and computational techniques. The protein was first identified in the brain using a technique called affinity purification, which allowed researchers to isolate and purify the protein from brain tissue. The amino acid sequence of SYNPR-AS1 was then determined through DNA sequencing.

SYNPR-AS1 is a member of the neurotransmitter receptor family, which includes other well-known molecules such as dopamine, serotonin, and norepinephrine. These molecules are involved in the regulation of various physiological processes, including mood, appetite, and sexual behavior. SYNPR-AS1 is specifically involved in the regulation of neuronal communication, and its function is to regulate the release of neurotransmitters from neurons.

Potential Drug Target

SYNPR-AS1 has been identified as a potential drug target due to its involvement in the regulation of neuronal communication. The regulation of neuronal communication is critical for the function of the brain, and disruptions in this process have been linked to a variety of neurological disorders, including depression, anxiety, and neurodegenerative diseases.

One of the potential mechanisms by which SYNPR-AS1 could be targeted as a drug is its role in the regulation of neurotransmitter release. The regulation of neurotransmitter release is a critical process that allows neurons to communicate with other neurons and the brain to regulate various physiological processes. Imbalances in neurotransmitter release have been linked to a variety of neurological disorders, including depression and anxiety.

SYNPR-AS1 has been shown to play a role in regulating neurotransmitter release by interacting with a variety of proteins, including the neurotransmitter receptor N-methyl-D-aspartate (NMDA)R1. This interaction between SYNPR-AS1 and NMDAR1 has been shown to play a role in the regulation of neurotransmitter release and may be a potential target for drug development.

Biomarker

SYNPR-AS1 has also been identified as a potential biomarker for a variety of neurological disorders, including depression, anxiety, and neurodegenerative diseases. The regulation of neuronal communication is a critical process that is affected by a variety of factors, including neurotransmitters, ion channels, and signaling pathways.

SYNPR-AS1 has been shown to play a role in the regulation of neuronal communication by interacting with the neurotransmitter receptor N-methyl-D-aspartate (NMDA)R1. This interaction between SYNPR-AS1 and NMDAR1 has been shown to play a role in the regulation of neurotransmitter release and may be a potential target for drug development.

Conclusion

SYNPR-AS1 is a protein that is expressed in the brain and is involved in the regulation of neuronal communication. Its potential as a drug target and biomarker has generated significant interest in recent years. The regulation of neuronal communication is a critical process that is affected by a variety of factors, including neurotransmitters, ion channels, and signaling pathways. Further research is needed to fully understand the function of SYNPR-AS1 and its potential as a drug target and biomarker.

Protein Name: SYNPR Antisense RNA 1

The "SYNPR-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYNPR-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets